Secukinumab

4 articles published between March 10, 2026 and September 25, 2026.

THE DRUG DOCKET

A biologic helped polymyalgia patients taper steroids in a phase 3 trial

REPLENISH randomised 381 patients with relapsed polymyalgia rheumatica. Sustained remission at 52 weeks reached about 41% on secukinumab versus 20.4% on placebo. Novartis funded the trial.

4 min read

ANALYSIS

Psoriasis is a systemic disease. Whether clearing the skin protects the heart is unsettled

Three 2025 reviews of the same drugs reach three answers: a matched cohort finds less cardiovascular disease on biologics, a network meta-analysis flags one drug as raising events, and 43 trials find nothing.

4 min read

WHAT THE STUDY ACTUALLY SAYS

Secukinumab missed its mark in a giant cell arteritis trial

In the phase 3 GCAptAIN trial the interleukin-17A blocker did not significantly beat placebo for sustained remission at one year, leaving the IL-6 inhibitor tocilizumab as the proven steroid-sparing option.

4 min read

WHAT THE STUDY ACTUALLY SAYS

An IL-17 drug helped children with hard-to-treat juvenile arthritis

In the COSPIRIT-JIA trial, most children with two stubborn forms of juvenile idiopathic arthritis responded to ixekizumab by week 16 — but the main result had no control group.

4 min read

This page indexes this newspaper’s reporting on Secukinumab. It is not a medical reference entry, and nothing here is medical advice. See our editorial standards.